Cargando…

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Pothin, Elodie, Lesuisse, Dominique, Lafaye, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601373/
https://www.ncbi.nlm.nih.gov/pubmed/33007904
http://dx.doi.org/10.3390/pharmaceutics12100937
_version_ 1783603400603074560
author Pothin, Elodie
Lesuisse, Dominique
Lafaye, Pierre
author_facet Pothin, Elodie
Lesuisse, Dominique
Lafaye, Pierre
author_sort Pothin, Elodie
collection PubMed
description Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood–brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
format Online
Article
Text
id pubmed-7601373
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76013732020-11-01 Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR Pothin, Elodie Lesuisse, Dominique Lafaye, Pierre Pharmaceutics Review Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood–brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools. MDPI 2020-09-30 /pmc/articles/PMC7601373/ /pubmed/33007904 http://dx.doi.org/10.3390/pharmaceutics12100937 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pothin, Elodie
Lesuisse, Dominique
Lafaye, Pierre
Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title_full Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title_fullStr Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title_full_unstemmed Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title_short Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
title_sort brain delivery of single-domain antibodies: a focus on vhh and vnar
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601373/
https://www.ncbi.nlm.nih.gov/pubmed/33007904
http://dx.doi.org/10.3390/pharmaceutics12100937
work_keys_str_mv AT pothinelodie braindeliveryofsingledomainantibodiesafocusonvhhandvnar
AT lesuissedominique braindeliveryofsingledomainantibodiesafocusonvhhandvnar
AT lafayepierre braindeliveryofsingledomainantibodiesafocusonvhhandvnar